nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2012-16-1-57-62nefr-566Research ArticleЖУРНАЛ В ЖУРНАЛЕ. АКТУАЛЬНЫЕ ПРОБЛЕМЫ УРОЛОГИИJOURNAL IN THE JOURNAL. ACTUAL PROBLEMS OF UROLOGYМЕДИКАМЕНТОЗНОЕ ЛЕЧЕНИЕ БОЛЬНЫХ С НЕЙРОГЕННОЙ ГИПЕРАКТИВНОСТЬЮ МОЧЕВОГО ПУЗЫРЯPHARMACEUTICAL TREATMENT OF PATIENTS WITH NEUROGENIC OVERACTIVE BLADDERАль-ШукриС.Х.Al-ShukriS.Kh.

Кафедра урологии

КузьминИ. В.KuzminI. V.

Кафедра урологии 

197022, Санкт-Петербург, ул. Льва Толстого, д. 17, тел. (812) 234-19-54

kuzminigor@mail.ruЛукинаЕ. Е.LukinaE. E.

Кафедра урологии

Санкт-Петербургский государственный медицинский университет им. акад. И.П.ПавловаRussian Federation2012100120121615762Copyright © Аль-Шукри С., Кузьмин И.В., Лукина Е.Е., 20122012Аль-Шукри С., Кузьмин И.В., Лукина Е.Е.Al-Shukri S., Kuzmin I.V., Lukina E.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/566

Гиперактивность мочевого пузыря (ГАМП) является одной из наиболее частых дисфункций нижних мочевых путей и клинически проявляется императивными позывами, учащением мочеиспускания и ургентным недержанием мочи. Антихолинергические препараты являются основой терапии больных с нейрогенной ГАМП. Они увеличивают емкость мочевого пузыря, снижают внутрипузырное давление, уменьшают интенсивность симптоматики ГАМП. Больным с нейрогенной ГАМП часто требуется назначать дозы антихолинергических препаратов, существенно превышающие таковые при лечении пациентов с идиопатической ГАМП. Кроме того, возможно комбинированное применение нескольких антихолинергических препаратов. Неэффективность или плохая переносимость пероральной медикаментозной терапии является показанием к внутрипузырному введению нейротоксинов, в первую очередь, ботулинического токсина.

Overactive bladder (OB) is one of the most frequent disfunction of lower urinary tract and clinically occurs by urgency, uresis acceleration and urge urinary continence. Anticholinergic medications are the base of neurogenic OB patients’s therapy. They increase bladder capacity, decrease intravesical pressure, reduce OB symptomatology intensity. Constantly patients with neurogenic OB need anticholinergic medications in higher doses then patients with idiopathic OB. Also, combined administration of several anticholinergic medicationbs is possible. Inefficiency or low tolerance to peroral drug therapy is an indication for neurotoxins intravesical administration, firstly botulinus toxin.

гиперактивность мочевого пузырялечениеoveractive bladdertreatmentReferencesAbrams P, Cardozo L, Fall M et al. The standartisation of terminology in lower urinary tract function: Report from the standartisation sub-committee of the International Continence Society. Neurourol Urodyn 2003; 21: 167-178Abrams P, Cardozo L, Fall M et al. The standartisation of terminology in lower urinary tract function: Report from the standartisation sub-committee of the International Continence Society. Neurourol Urodyn 2003; 21: 167-178Hunskaar S, Arnold EP, Burgio K et al. Epidemiology and natural history of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 2st International Consultation on Incontinence, July 1-3, 2002, 2nd ed. Health Publication Ltd, Plymouth, UK, 2002; 167-201Hunskaar S, Arnold EP, Burgio K et al. Epidemiology and natural history of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 2st International Consultation on Incontinence, July 1-3, 2002, 2nd ed. Health Publication Ltd, Plymouth, UK, 2002; 167-201De Groat WC. A neurologic basis for the overactive bladder. Urology 1997; 50 (6A Suppl): 36-52De Groat WC. A neurologic basis for the overactive bladder. Urology 1997; 50 (6A Suppl): 36-52De Groat WC, Booth AM, Yoshimura N. Neurophysiology of micturition and its modification in animal models of human disease. In: Maggi CA, ed. The autonomic nervous system, Vol.3, Chapter 8, Nervous control of the urogenital system. Harwood Academic Publishers, London, UK, 1993: 227-290De Groat WC, Booth AM, Yoshimura N. Neurophysiology of micturition and its modification in animal models of human disease. In: Maggi CA, ed. The autonomic nervous system, Vol.3, Chapter 8, Nervous control of the urogenital system. Harwood Academic Publishers, London, UK, 1993: 227-290Stöhrer М, Blok B, Castro-Diaz D.et al. EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction. Eur Urol 2009; 56 (1): 81-88Stöhrer М, Blok B, Castro-Diaz D.et al. EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction. Eur Urol 2009; 56 (1): 81-88Donnelly J, Hackler RH, Bunts RC. Present urologic status of the World War II paraplegic: 25-year follow-up. Comparison with status of the 20-year Korean War paraplegic and 5-year Vietnam paraplegic. J Urol 1972; 108 (4): 558-562Donnelly J, Hackler RH, Bunts RC. Present urologic status of the World War II paraplegic: 25-year follow-up. Comparison with status of the 20-year Korean War paraplegic and 5-year Vietnam paraplegic. J Urol 1972; 108 (4): 558-562Game X, Castel-Lacanal E, Bentaleb Y et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2007; 53 (3): 613-619Game X, Castel-Lacanal E, Bentaleb Y et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2007; 53 (3): 613-619Castro-Diaz D, Barrett D, Grise P et al. Surgery for the neuropathic patient. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 2st International Consultation on Incontinence, July 1-3, 2002, 2nd ed. Health Publication Ltd, Plymouth, UK, 2002; 865-891Castro-Diaz D, Barrett D, Grise P et al. Surgery for the neuropathic patient. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 2st International Consultation on Incontinence, July 1-3, 2002, 2nd ed. Health Publication Ltd, Plymouth, UK, 2002; 865-891Appell RA. Overactive bladder in special patient populations. Rev Urol 2003; 5 (8): 37-41Appell RA. Overactive bladder in special patient populations. Rev Urol 2003; 5 (8): 37-41Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 2006; 85: 536–545Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 2006; 85: 536–545Diokno A, Ingber M. Oxybutynin in detrusor overactivity. Urol Clin N Am 2006; 33 (4): 439-445Diokno A, Ingber M. Oxybutynin in detrusor overactivity. Urol Clin N Am 2006; 33 (4): 439-445O’Leary M, Erickson JR, Smith CP et al. Effect of controlledrelease oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 2003; 26 (2): 159-162O’Leary M, Erickson JR, Smith CP et al. Effect of controlledrelease oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 2003; 26 (2): 159-162Bennett N, O’Leary M, Patel AS et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004; 171 (2 Pt 1): 749-751Bennett N, O’Leary M, Patel AS et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004; 171 (2 Pt 1): 749-751Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology 2009; 74 (4): 741-745Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology 2009; 74 (4): 741-745Stohrer M, Murtz G, Kramer G et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity – results of a randomized, doubleblind, multicenter clinical study. Eur Urol 2007; 51 (1): 235–242Stohrer M, Murtz G, Kramer G et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity – results of a randomized, doubleblind, multicenter clinical study. Eur Urol 2007; 51 (1): 235–242Wyndaele JJ, Castro D, Madersbacher H et al. Neurologic urinary and fecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, Vol.2. Health Publication Ltd, Plymouth, UK, 2005; 1059–1062Wyndaele JJ, Castro D, Madersbacher H et al. Neurologic urinary and fecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, Vol.2. Health Publication Ltd, Plymouth, UK, 2005; 1059–1062Lehtoranta K, Tainio H, Lukkari-Lax E et al. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol 2002; 36(1): 18-24Lehtoranta K, Tainio H, Lukkari-Lax E et al. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol 2002; 36(1): 18-24Ethans KD, Nance PW, Bard RJ et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004; 27: 214–218Ethans KD, Nance PW, Bard RJ et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004; 27: 214–218Horstmann M, Schaefer T, Aguilar Y et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006; 25 (5): 441-445Horstmann M, Schaefer T, Aguilar Y et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006; 25 (5): 441-445Menarini M, Del Popolo G, Di Benedetto P et al. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 2006; 44(12): 623-632Menarini M, Del Popolo G, Di Benedetto P et al. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 2006; 44(12): 623-632Stöhrer M, Bauer P, Giannetti BM et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebocontrolled double-blind trial. Urol Int 1991; 47 (3): 138-143Stöhrer M, Bauer P, Giannetti BM et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebocontrolled double-blind trial. Urol Int 1991; 47 (3): 138-143Bycroft J, Leaker B, Wood S et al. The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury. In: Proceedings of 33st Annual Meeting of International Continence Society. Florence, Italy, 2003; Abstract 190Bycroft J, Leaker B, Wood S et al. The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury. In: Proceedings of 33st Annual Meeting of International Continence Society. Florence, Italy, 2003; Abstract 190Carl S, Laschke S. Darifenacin is also effective in neurogenic bladder dysfunction (multiple sclerosis). Urology 2006; 68 [suppl]: 250Carl S, Laschke S. Darifenacin is also effective in neurogenic bladder dysfunction (multiple sclerosis). Urology 2006; 68 [suppl]: 250Chapple CR, Araño P, Bosch JL et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dosefinding study. BJU Int 2004; 93: 71–77Chapple CR, Araño P, Bosch JL et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dosefinding study. BJU Int 2004; 93: 71–77Cardozo L, Lisec M, Millard R et al. Randomized, doubleblind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919–1924Cardozo L, Lisec M, Millard R et al. Randomized, doubleblind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919–1924Suzuki M, Ohtake A, Yoshino T et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infracted rats. Eur J Pharmacol 2005; 512 (1): 61–66Suzuki M, Ohtake A, Yoshino T et al. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infracted rats. Eur J Pharmacol 2005; 512 (1): 61–66Fowler CJ, Griffiths D, De Groat WC. The neural control of micturition. Nat Rev Neurosci 2008; 9 (6): 453-466Fowler CJ, Griffiths D, De Groat WC. The neural control of micturition. Nat Rev Neurosci 2008; 9 (6): 453-466Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol 1998; 275 (5): 1654-1660Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol 1998; 275 (5): 1654-1660Amend B, Hennenlotter J, Schäfer T el. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008; 53(5): 1021-1028Amend B, Hennenlotter J, Schäfer T el. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008; 53(5): 1021-1028Gacci M, Del Popolo G, Macchiarella A et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007; 178 (5): 2040- 2043Gacci M, Del Popolo G, Macchiarella A et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007; 178 (5): 2040- 2043Chancellor MB, Rivas DA, Staas WE Jr. DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury: preliminary report. J Am Paraplegia Soc 1994; 17 (4): 165-167Chancellor MB, Rivas DA, Staas WE Jr. DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury: preliminary report. J Am Paraplegia Soc 1994; 17 (4): 165-167Valiquette G, Herbert J, Maede-D’Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996; 53 (12): 1270- 1275Valiquette G, Herbert J, Maede-D’Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996; 53 (12): 1270- 1275Fowler CJ, Beck RO, Gerrard S et al. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57(2): 169-173Fowler CJ, Beck RO, Gerrard S et al. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57(2): 169-173Fowler CJ, Jewkes D, McDonald WI et al. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992; 339 (8803): 1239Fowler CJ, Jewkes D, McDonald WI et al. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992; 339 (8803): 1239De Seze M, Wiart L, Joseph PA et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998; 17 (5): 513–523De Seze M, Wiart L, Joseph PA et al. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998; 17 (5): 513–523De Ridder D, Chandiramani V, Dasgupta P et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow-up. J Urol 1997; 158 (6): 2087-2092De Ridder D, Chandiramani V, Dasgupta P et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow-up. J Urol 1997; 158 (6): 2087-2092Chancellor MB, De Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999; 162(1): 3-11Chancellor MB, De Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999; 162(1): 3-11Giannantoni A, Di Stasi SM, Stephen RL et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 2002; 167(4): 1710-1714Giannantoni A, Di Stasi SM, Stephen RL et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 2002; 167(4): 1710-1714Kuo HC. Effectiveness of intravesical resiniferatoxin in treating detrusor hyper-reflexia and external sphincter dyssynergia in patients with chronic spinal cord lesions. BJU Int 2003; 92 (6): 597-601.Kuo HC. Effectiveness of intravesical resiniferatoxin in treating detrusor hyper-reflexia and external sphincter dyssynergia in patients with chronic spinal cord lesions. BJU Int 2003; 92 (6): 597-601.Coffield JA, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet M, eds. Therapy With Botulinum Toxin. Marcel Dekker, New York, 1994: 3–13Coffield JA, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet M, eds. Therapy With Botulinum Toxin. Marcel Dekker, New York, 1994: 3–13Мазо ЕБ, Кривобородов ГГ. Гиперактивный мочевой пузырь. Вече, М., 2003; 160Мазо ЕБ, Кривобородов ГГ. Гиперактивный мочевой пузырь. Вече, М., 2003; 160Schurch B, Stohrer M, Kramer G et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164 (3): 692-697Schurch B, Stohrer M, Kramer G et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164 (3): 692-697Rajkumar GN, Conn IG. Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction.Urology 2004; 64 (1): 2-8Rajkumar GN, Conn IG. Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction.Urology 2004; 64 (1): 2-8Madersbacher H, Wyndaele JJ, Igawa Y et al. Conservative management in neuropatic urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 2st International Consultation on Incontinence, July 1-3, 2002, 2nd ed. Health Publication Ltd, Plymouth, UK, 2002; 697-754Madersbacher H, Wyndaele JJ, Igawa Y et al. Conservative management in neuropatic urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence: 2st International Consultation on Incontinence, July 1-3, 2002, 2nd ed. Health Publication Ltd, Plymouth, UK, 2002; 697-754Abrams P, Amarenco G, Bakke A et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003; 170 (4): 1242-1251Abrams P, Amarenco G, Bakke A et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003; 170 (4): 1242-1251

The authors declare that there are no conflicts of interest present.